During the past decade, Abington Neurological Associates conducted 59 clinical trials. In the 10-year time frame, 59 clinical trials started and 30 clinical trials were completed, i.e. on average, 50.8% percent of trials that started reached the finish line to date. In the past 5 years, 29 clinical trials started and 21 clinical trials were completed. i.e. 72.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Abington Neurological Associates" #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "Eli Lilly and Company" with 10 trials sponsored, "Pfizer" with 4 trials sponsored, "Allergan" with 3 trials sponsored and "Genentech, Inc." with 3 trials sponsored. Other sponsors include 32 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Abington Neurological Associates" #1 collaborator was "National Institute on Aging (NIA)" with 7 trials as a collaborator, "Alzheimer's Disease Cooperative Study (ADCS)" with 3 trials as a collaborator, "Pfizer" with 3 trials as a collaborator, "Alzheimer's Clinical Trials Consortium" with 2 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Abington Neurological Associates" are "Alzheimer Disease" (20 trials), "Alzheimer's Disease" (14 trials), "Dementia" (4 trials), "Multiple Sclerosis" (4 trials) and "Alzheimers Disease" (3 trials). Many other conditions were trialed in "Abington Neurological Associates" in a lesser frequency.

Most popular intervention types in "Abington Neurological Associates" are "Drug" (66 trials), "Other" (3 trials), "Biological" (2 trials), "Procedure" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (34 trials), "Gantenerumab" (4 trials), "Ocrelizumab" (4 trials), "Bapineuzumab 0.5 mg/kg" (3 trials) and "Crenezumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Abington Neurological Associates" are 70 trials for "All" genders.

Currently, there are NaN active trials in "Abington Neurological Associates". undefined are not yet recruiting, 14 are recruiting, 9 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 24 completed trials in Abington Neurological Associates, 1 suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in Abington Neurological Associates, 3 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".